Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genital examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Genital examination. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-003586-35 Sponsor Protocol Number: 215336 Start Date*: 2022-01-25
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy parti...
    Medical condition: Recurrent genital herpes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10018150 Genital herpes PT
    21.1 10021881 - Infections and infestations 10073931 Genital herpes simplex PT
    24.0 10021881 - Infections and infestations 10084891 Anal herpes LLT
    20.1 10021881 - Infections and infestations 10054225 Anogenital herpes LLT
    20.1 10021881 - Infections and infestations 10018151 Genital herpes, unspecified LLT
    20.0 10021881 - Infections and infestations 10019937 Herpes genital LLT
    20.0 10021881 - Infections and infestations 10019938 Herpes genitalis LLT
    20.0 10021881 - Infections and infestations 10019997 Herpetic infection of penis LLT
    20.1 10021881 - Infections and infestations 10020003 Herpetic ulceration of vulva LLT
    20.1 10021881 - Infections and infestations 10020004 Herpetic vulvovaginitis LLT
    21.1 10021881 - Infections and infestations 10065050 Perianal herpes simplex LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005553-13 Sponsor Protocol Number: CLS001-CO-PR-011 Start Date*: 2016-05-11
    Sponsor Name:Cutanea Life Sciences
    Full Title: A PHASE 2, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EXPLORE THE PHARMACODYNAMICS, SAFETY AND EFFICACY OF TOPICAL OMIGANAN IN PATIENTS WITH EXTERNAL GENITAL WARTS
    Medical condition: Patients with external genital warts
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10018182 Genital warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000870-39 Sponsor Protocol Number: CHDR1607 Start Date*: 2017-08-21
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide i...
    Medical condition: HPV-induced genital lesions of immunocompromised and immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10018182 Genital warts LLT
    20.0 100000024086 10064455 HSIL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002608-15 Sponsor Protocol Number: CC-10004-PSOR-025 Start Date*: 2019-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis
    Medical condition: MODERATE TO SEVERE GENITAL PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10063407 Psoriasis genital LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002108-25 Sponsor Protocol Number: CC-10004-BCT-002 Start Date*: 2015-06-17
    Sponsor Name:Amgen Inc.
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE...
    Medical condition: SUBJECTS WITH ACTIVE BEHÇET’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002009-31 Sponsor Protocol Number: EB069 Start Date*: 2007-06-13
    Sponsor Name:Emotional Brain BV
    Full Title: A double blind randomized placebo controlled cross-over study to validate the distinction between women with different levels of attention and valence direction for erotic stimuli, in relation with...
    Medical condition: Hypoactive sexual desire disorder and female sexual arousal disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002190-37 Sponsor Protocol Number: P140302 Start Date*: 2015-10-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in patients with Behçet disease : STELABEC
    Medical condition: Behçet disease STELABEC-1: patients with oral ulcers STELABEC-2 : patients with active posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002787-27 Sponsor Protocol Number: 20190530 Start Date*: 2021-03-15
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From ...
    Medical condition: Subjects with active Behçet’s Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003778-16 Sponsor Protocol Number: J005 Start Date*: 2013-04-24
    Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust
    Full Title: A phase IV study to determine the oral and genital tract concentration of Maraviroc required for ex vivo protection from HIV-1 using Maraviroc 300mg stat
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001731-55 Sponsor Protocol Number: 106636 Start Date*: 2007-08-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10008230 Cervix neoplasms malignant HLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-003399-10 Sponsor Protocol Number: GDS07C Start Date*: 2014-03-24
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerabi...
    Medical condition: Prevention of premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer and genital warts (condyloma acuminata) causally related to Human Papillomavirus (HPV) Types 6, 11, 16,...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10061331 Papilloma viral infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000109-19 Sponsor Protocol Number: V502-001 Start Date*: 2017-01-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58...
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000108-42 Sponsor Protocol Number: V505-001 Start Date*: 2017-01-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particl...
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002932-42 Sponsor Protocol Number: V501-110-01 Start Date*: 2016-12-14
    Sponsor Name:MSD K.K., a subsidiary of Merck & Co., Inc
    Full Title: A Phase IV Open-label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 ...
    Medical condition: Human Papillomavirus infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023254-36 Sponsor Protocol Number: GUMPID002 Start Date*: 2011-06-22
    Sponsor Name:Brighton and Sussex University Hospitals NHS Trust
    Full Title: Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?
    Medical condition: Pelvic Inflammatory Disease (PID)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10034254 Pelvic inflammatory disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005987-15 Sponsor Protocol Number: The Triple P study Start Date*: 2009-10-22
    Sponsor Name:AMC Amsterdam
    Full Title: Preventing preterm birth: Costs and effects of screening of healthy women with a singleton pregnancy for a short cervical length.
    Medical condition: Preterm birth with healthy singleton pregnancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036600 Premature labour LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005093-38 Sponsor Protocol Number: V503-004 Start Date*: 2016-07-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27-...
    Medical condition: Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061331 Papilloma viral infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) FI (Completed) AT (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023393-39 Sponsor Protocol Number: GDS01C Start Date*: 2011-01-13
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Toler...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066416 Vulvovaginal human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) BE (Completed) SE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 13:37:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA